FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2228636571> ?p ?o ?g. }

• W2228636571 endingPage "1779" @default.
• W2228636571 startingPage "1779" @default.
• W2228636571 abstract "PURPOSE: To determine the efficacy and tolerance of single-agent docetaxel and granulocyte colony-stimulating factor in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Thirty-three chemotherapy-naive patients (median age, 65 years) with histologically confirmed pancreatic cancer were treated, after appropriate premedication, with docetaxel (100 mg/m 2 ) and granulocyte colony-stimulating factor (150 μg/m 2 /d subcutaneously days 2 through 10) every 3 weeks. World Health Organization performance status was 0 to 1 in 28 patients (85%) and 2 in 5 patients (15%). Twenty-nine patients had stage III and IV disease. RESULTS: One complete response (3%) and one partial response (3%) were observed for an overall response rate of 6% (95% confidence interval, 2.1% to 14.2%). Nineteen patients (58%) had stable disease and 12 (36%) had progressive disease. The duration of the two objective responses was 10 and 28 weeks, and the median time to tumor progression was 20 weeks. The median overall survival was 36 weeks. The actuarial 1-year survival was 36.4%. The performance status improved in seven of 21 assessable patients (24%) and pain improved in 14 of 21 (67%) assessable patients; five patients (29%) experienced weight gain during treatment. Disease-related asthenia, anorexia, vomiting, and diarrhea improved in 29%, 15%, 67%, and 47% of the assessable patients, respectively. Serum concentrations of CA 19-9 were decreased by more than 50% in seven patients (35%). Grade 3 and 4 neutropenia occurred in four patients (12%) and eight patients (24%), respectively, with two episodes of febrile neutropenia. There were no treatment-related deaths. Grade 3/4 asthenia occurred in three patients. CONCLUSION: Although docetaxel has a marginal objective activity in pancreatic cancer, it seems to have an important effect on tumor growth control, conferring a clinical benefit." @default.
• W2228636571 created "2016-06-24" @default.
• W2228636571 creator A5001430197 @default.
• W2228636571 creator A5011732363 @default.
• W2228636571 creator A5012405296 @default.
• W2228636571 creator A5019789502 @default.
• W2228636571 creator A5027807165 @default.
• W2228636571 creator A5056643910 @default.
• W2228636571 creator A5068888404 @default.
• W2228636571 creator A5071722373 @default.
• W2228636571 creator A5083766590 @default.
• W2228636571 creator A5084377238 @default.
• W2228636571 creator A5087479328 @default.
• W2228636571 creator A5091632911 @default.
• W2228636571 date "1999-06-01" @default.
• W2228636571 modified "2023-10-18" @default.
• W2228636571 title "Treatment of Pancreatic Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor: A Multicenter Phase II Study" @default.
• W2228636571 cites W1771666756 @default.
• W2228636571 cites W1931508686 @default.
• W2228636571 cites W1936178215 @default.
• W2228636571 cites W1985287393 @default.
• W2228636571 cites W2014184691 @default.
• W2228636571 cites W2024210946 @default.
• W2228636571 cites W2028214212 @default.
• W2228636571 cites W2042653326 @default.
• W2228636571 cites W2043478531 @default.
• W2228636571 cites W2073533584 @default.
• W2228636571 cites W2084562398 @default.
• W2228636571 cites W2086159044 @default.
• W2228636571 cites W2135352785 @default.
• W2228636571 cites W2167805334 @default.
• W2228636571 cites W2740368365 @default.
• W2228636571 cites W4293241248 @default.
• W2228636571 cites W630333438 @default.
• W2228636571 doi "https://doi.org/10.1200/jco.1999.17.6.1779" @default.
• W2228636571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10561215" @default.
• W2228636571 hasPublicationYear "1999" @default.
• W2228636571 type Work @default.
• W2228636571 sameAs 2228636571 @default.
• W2228636571 citedByCount "74" @default.
• W2228636571 countsByYear W22286365712012 @default.
• W2228636571 countsByYear W22286365712013 @default.
• W2228636571 countsByYear W22286365712014 @default.
• W2228636571 countsByYear W22286365712015 @default.
• W2228636571 countsByYear W22286365712016 @default.
• W2228636571 countsByYear W22286365712017 @default.
• W2228636571 countsByYear W22286365712018 @default.
• W2228636571 countsByYear W22286365712019 @default.
• W2228636571 crossrefType "journal-article" @default.
• W2228636571 hasAuthorship W2228636571A5001430197 @default.
• W2228636571 hasAuthorship W2228636571A5011732363 @default.
• W2228636571 hasAuthorship W2228636571A5012405296 @default.
• W2228636571 hasAuthorship W2228636571A5019789502 @default.
• W2228636571 hasAuthorship W2228636571A5027807165 @default.
• W2228636571 hasAuthorship W2228636571A5056643910 @default.
• W2228636571 hasAuthorship W2228636571A5068888404 @default.
• W2228636571 hasAuthorship W2228636571A5071722373 @default.
• W2228636571 hasAuthorship W2228636571A5083766590 @default.
• W2228636571 hasAuthorship W2228636571A5084377238 @default.
• W2228636571 hasAuthorship W2228636571A5087479328 @default.
• W2228636571 hasAuthorship W2228636571A5091632911 @default.
• W2228636571 hasConcept C121608353 @default.
• W2228636571 hasConcept C126322002 @default.
• W2228636571 hasConcept C141071460 @default.
• W2228636571 hasConcept C2776694085 @default.
• W2228636571 hasConcept C2776737053 @default.
• W2228636571 hasConcept C2777063308 @default.
• W2228636571 hasConcept C2777767877 @default.
• W2228636571 hasConcept C2778764654 @default.
• W2228636571 hasConcept C2778822529 @default.
• W2228636571 hasConcept C2780210213 @default.
• W2228636571 hasConcept C2781190966 @default.
• W2228636571 hasConcept C71924100 @default.
• W2228636571 hasConcept C90924648 @default.
• W2228636571 hasConceptScore W2228636571C121608353 @default.
• W2228636571 hasConceptScore W2228636571C126322002 @default.
• W2228636571 hasConceptScore W2228636571C141071460 @default.
• W2228636571 hasConceptScore W2228636571C2776694085 @default.
• W2228636571 hasConceptScore W2228636571C2776737053 @default.
• W2228636571 hasConceptScore W2228636571C2777063308 @default.
• W2228636571 hasConceptScore W2228636571C2777767877 @default.
• W2228636571 hasConceptScore W2228636571C2778764654 @default.
• W2228636571 hasConceptScore W2228636571C2778822529 @default.
• W2228636571 hasConceptScore W2228636571C2780210213 @default.
• W2228636571 hasConceptScore W2228636571C2781190966 @default.
• W2228636571 hasConceptScore W2228636571C71924100 @default.
• W2228636571 hasConceptScore W2228636571C90924648 @default.
• W2228636571 hasIssue "6" @default.
• W2228636571 hasLocation W22286365711 @default.
• W2228636571 hasLocation W22286365712 @default.
• W2228636571 hasOpenAccess W2228636571 @default.
• W2228636571 hasPrimaryLocation W22286365711 @default.
• W2228636571 hasRelatedWork W2031089613 @default.
• W2228636571 hasRelatedWork W2031646868 @default.
• W2228636571 hasRelatedWork W2061928026 @default.
• W2228636571 hasRelatedWork W2085307618 @default.
• W2228636571 hasRelatedWork W2106964779 @default.
• W2228636571 hasRelatedWork W2114989931 @default.

• next